



## Erratum

To cite this article: (2011) Erratum, Expert Opinion on Emerging Drugs, 16:4, 731-731, DOI: [10.1517/14728214.2011.635005](https://doi.org/10.1517/14728214.2011.635005)

To link to this article: <https://doi.org/10.1517/14728214.2011.635005>



Published online: 04 Nov 2011.



Submit your article to this journal [↗](#)



Article views: 248



View related articles [↗](#)

*Expert Opinion on Emerging Drugs* wishes to inform its readers of the following incident of redundant publication.

The following publication:

Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma *Expert Opin Emerg Drugs* 2006 Sep;11(3):469-87 [1] contains information reported also in the previously published article, Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. *Semin Liver Dis* 2005;25(2):212-25 [2], without adequately referencing the prior publication.

Although Roberts and Gores [1] report considerable additional information not contained in [2], *Expert Opinion on Emerging Drugs* regrets that the earlier publication was not adequately referenced. The editors of *Expert Opinion on Emerging Drugs* were not fully apprised by the authors of the prior publication and discovered the modest overlap only after it was highlighted to the editors after publication.

### **Bibliography**

1. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. *Expert Opin Emerg Drugs* 2006;11(4):469-87
2. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. *Semin Liver Dis* 2005;25(2):212-25